$4.11 Billion in Sales Expected for Stryker Co. (NYSE:SYK) This Quarter

Equities research analysts expect that Stryker Co. (NYSE:SYK) will announce sales of $4.11 billion for the current fiscal quarter, Zacks reports. Eleven analysts have issued estimates for Stryker’s earnings, with the lowest sales estimate coming in at $3.90 billion and the highest estimate coming in at $4.25 billion. Stryker reported sales of $2.76 billion during the same quarter last year, which would suggest a positive year over year growth rate of 48.9%. The business is expected to report its next quarterly earnings report on Thursday, July 29th.

According to Zacks, analysts expect that Stryker will report full year sales of $17.13 billion for the current financial year, with estimates ranging from $16.94 billion to $17.29 billion. For the next financial year, analysts forecast that the business will report sales of $18.28 billion, with estimates ranging from $18.02 billion to $18.48 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that follow Stryker.

Stryker (NYSE:SYK) last released its quarterly earnings data on Monday, April 26th. The medical technology company reported $1.93 EPS for the quarter, missing the consensus estimate of $1.99 by ($0.06). Stryker had a return on equity of 20.94% and a net margin of 12.35%. The business had revenue of $3.95 billion during the quarter, compared to analysts’ expectations of $3.94 billion. During the same quarter in the prior year, the firm earned $1.84 earnings per share. Stryker’s quarterly revenue was up 10.2% on a year-over-year basis.

A number of research firms have issued reports on SYK. Deutsche Bank Aktiengesellschaft upped their target price on shares of Stryker from $251.00 to $285.00 and gave the company a “buy” rating in a report on Wednesday, April 28th. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell upped their target price on shares of Stryker from $264.00 to $303.00 in a report on Wednesday, April 28th. Morgan Stanley upped their target price on shares of Stryker from $265.00 to $280.00 and gave the company an “overweight” rating in a report on Tuesday. Raymond James upped their target price on shares of Stryker from $255.00 to $290.00 and gave the company an “outperform” rating in a report on Tuesday. Finally, Truist Securities upped their price objective on shares of Stryker from $245.00 to $255.00 in a research note on Wednesday, April 28th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and thirteen have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $261.59.

In other news, CFO Glenn S. Boehnlein sold 2,000 shares of the stock in a transaction that occurred on Monday, March 1st. The stock was sold at an average price of $246.01, for a total transaction of $492,020.00. Following the completion of the transaction, the chief financial officer now directly owns 12,321 shares in the company, valued at approximately $3,031,089.21. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP M Kathryn Fink sold 4,000 shares of the stock in a transaction that occurred on Thursday, April 8th. The shares were sold at an average price of $250.00, for a total value of $1,000,000.00. The disclosure for this sale can be found here. 6.80% of the stock is owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the company. Curi Capital purchased a new position in shares of Stryker during the 4th quarter valued at approximately $29,000. RWM Asset Management LLC bought a new position in Stryker during the fourth quarter worth $33,000. Albion Financial Group UT bought a new position in Stryker during the fourth quarter worth $34,000. Ossiam lifted its stake in Stryker by 294.9% during the fourth quarter. Ossiam now owns 154 shares of the medical technology company’s stock worth $38,000 after purchasing an additional 115 shares during the last quarter. Finally, Graves Light Private Wealth Management Inc. bought a new position in Stryker during the fourth quarter worth $41,000. Institutional investors own 71.46% of the company’s stock.

NYSE:SYK traded down $7.51 on Tuesday, reaching $255.59. The stock had a trading volume of 1,471,171 shares, compared to its average volume of 1,198,191. The company has a market cap of $96.29 billion, a price-to-earnings ratio of 55.44, a P/E/G ratio of 2.79 and a beta of 0.87. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.89 and a quick ratio of 2.15. The firm’s fifty day moving average is $249.58 and its two-hundred day moving average is $238.32. Stryker has a 12-month low of $171.75 and a 12-month high of $268.04.

Stryker Company Profile

Stryker Corp. engages in the provision of medical technology products and services. It operates through the following segments: Orthopaedics, MedSurg and Neurotechnology and Spine. The Orthopaedics segment provides reconstructive and trauma implant systems. The MedSurg segment deals with surgical equipment and navigation systems, endoscopy, patient handling and reprocessed medical devices.

Read More: What is Call Option Volume?

Get a free copy of the Zacks research report on Stryker (SYK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.